Archives: Agenda

PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS

During the roundtable discussion session, the conference hall will be divided into four ‘zones’. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within oncology clinical trials. After 45 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1: Discussing how sponsors can maximize patient recruitment including ethnic minorities in present US market climate

Cameron McClure, Associate Director, Global Clinical Operations, Clinical Trial Diversity, BeiGene

ROUNDTABLE 2: Finding the right protocol design and using right data to leverage oncology trials

Jill Hacker, Director of Data Management, InstilBio

ROUNDTABLE 3: Focusing on patient centricity and how sponsors are creating better patient experience?

Christine Von Raesfeld, Founder and CEO, People with Empathy

ROUNDTABLE 4: Improving outcomes by tailoring cancer therapy for patients without targetable mutations

Chris Apfel, CEO and Chairman, SageMedic Corporation

Retroviruses as novel targets for solid tumor immunotherapy

• Developing therapeutics that target human endogenous retrovirus (HERV) sequences, which comprise 8% of the total human genome DNA, and are overexpressed in solid tumors
• Generating long-term and durable anti-tumor responses to HERV type K (HERV-K)
• Priming and maintaining immune responses with therapeutic and preventative anti-HERV-K cancer vaccines
• Targeting tumor delivery of HERV-K RNA-encoded antigenic epitopes, antibodies, ADCs, CAR-T, bispecific antibodies (BiTEs), and tumor-infiltrating lymphocytes (TILs)
• Counter-regulating tumor microenvironment with HERV-K therapeutics
• Advancing new HERV-K companion diagnostics to monitor cancer early detection and recurrence

Getting hard feasibility data: how to do it

  • How do you access current, hard feasibility data?
  • Does your CRO have a stable, permanent clinical team with trial legacy capability and expertise in your domain?
  • Are your sites and vendors audit proof, and how can you enhance continuous improvement by formally adopting Lean?
  • Are you confident your CRO has the capacity to achieve your study milestones on or before deadline?
  • Is your CRO independent, does it act like a SMO with a dedicated site network?
  • Is it well-rounded in regard to systems, with a collaborative vendor team?